S-adenosyl-L-methionine for alcoholic liver diseases

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 11, 2015, Pages

  Rambaldi, Andrea ^a   Gluud, Christian ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RETRACTED ARTICLE; REVIEW; HUMAN; LIVER DISEASES, ALCOHOLIC; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

S ADENOSYLMETHIONINE;

HUMANS; LIVER DISEASES, ALCOHOLIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; S-ADENOSYLMETHIONINE;

EID: 84964693488     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002235.pub3     Document Type: Review

References (102)

1. Altomare E, Vendemiale G, Marchesini G, Le Grazie C, Di Padova C. Increased bioavailability of sulfurated compounds after s-adenosylmethionine (SAMe) administration to alcoholics. In: Kuriyama K, Takada A, Ishii H editor(s). Biomedical and social aspects of alcohol and alcoholism. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Devision), 1988:353-6.
2. Chawla RK, Gaetke L, McClain C. S-adenosylmethionine (Adomet) and plasma methionine clearance in alcoholic subjects. Hepatology 1999;30(4):397A.
3. Cibin M, Gentile N, Ferri M, Canton G, Le Grazie C, Gallimberti L. S-adenosylmethionine (SAMe) is effective in reducing ethanol abuse in an outpatient program for alcoholics. In: Kuriyama K, Takada A, Ishii H editor(s). Biomedical and social aspects of alcohol and alcoholism. Amsterdam: Elsevier Science Publishers BV (Biomedical Division), 1988:357-60.
4. Corrales F, Pajares M, Pliego M, Ortiz P, Moreno J, Puerta J, et al. Effect of S-adenosylmethionine treatment on methionine intolerance in alcoholic cirrhosis. Journal of Hepatology 1991;13(Suppl 2):S111.
5. Diaz Belmont A, Dominguez Henkel R, Uribe Ancira F. SAMe parenteral in the treatment of the alcoholic liver disease compared against placebo [SAMe parenteral en el tratamiento de la hepatopatia alcoholica comparativo contra placebo]. Anales de Medicina Interna 1996;13(1):9-15.
6. Loguercio C, Nardi G, Argenzio F, Aurilio C, Petrone E, Grella A, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol and Alcoholism 1994;29(5):597-604.
7. Caballería J, Rodés J. S-Adenosylmethionine in alcoholic liver disease. In: Leuschner U, James O, Dancygier H editor(s). Steatohepatitis (NASH and ASH). FALK Symposium 121. Dordrecht: Kluwer Academic Publishers, 2001:362-6.
8. Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Journal of Hepatology 1999;30:1081-9.
9. Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, et al. S-adenosylmethionine in the treatment of alcoholic liver cirrhosis. Results from a multicentric, placebo-contolled, randomized, double-blind, trial. Hepatology 1997;26(4):251A.
10. Trespi E, Vigoni R, Matti C, Colla C. TUDCA, UDCA, and ademethionine (Ade) in the treatment of alcohol-induced liver damage. Journal of Hepatology 1997;26(suppl 1):4407.
11. Altomare E, Vendemiale G, Marchesini G, Le Grazie C, Di Padova C. Increased bioavailability of sulfurated compounds after S-adenosylmethionine (SAMe) administration to alcoholics. In: Kuriyama K, Takada A, Ishii H editor(s). Biomedical and social aspects of alcohol and alcoholism. Amsterdam: Elsevier Science Publishers BV (Biomedical Division), 1988:353-6.
12. Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scandinavian Journal of Gastroenterology 1989;24:407-12.
13. Vendemiale G, Altomare E, Trizio T, Salerno MT, Carrieri V, Albano O. S-adenosylmethionine administration increases hepatic glutathione in patients with chronic liver disease. Journal of Hepatology 1987;5(Suppl 1):S218.
14. Agricola R, Dalla Verde G, Urani R, Di Palma C, Giorgetti V. S-adenosyl-L-methionine in the treatment of major depression complicating chronic alcoholism. Current Therapeutic Research 1994;55(1):83-92.
15. Avogaro P, Cazzolato G, Quinci GB, Bittolo Bon G. Variations of plasma apolipoproteins A1 and B induced in liver patients by infusions of S-adenosyl-L-methionine. Pharmacological Research Communications 1979;11(8):681-91.
16. Caballeria E, Moreno J. Therapeutic effects of S-adenosylmethionine (SAMe) in hepatic steatosis. A pilot study. Acta Therapeutica 1990;16:253-64.
17. Cabrero C, Duce AM, Ortiz P, Alemany S, Mato JM. Specific loss of the high-molecular-weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. Hepatology 1988;8(6):1530-4.
18. Di Padova C, Tritapepe R, Rovagnati P, Pozzoli M, Stramentinoli G. Decreased blood levels of ethanol and acetaldehyde by S-adenosyl-L-methionine in humans. Archives of Toxicology 1984;Suppl 7:7240-2. [MEDLINE: 85096255]
19. Fiaccadori F, Di Padova C, Ghinelli F, Magnani G, Pelosi G, Sacchini D. Effects of S-adenosyl-L-methionine (SAMe) on alcoholic liver disease in humans. Hepatology 1982;2(1):179.
20. Frezza M, Terpin MM, Peri A. The role of S-adenosyl-L-methionine in the treatment of some hepatic dysfunction [L'S-adenosil-L-methionina (SAMe) e il suo uso in epatologia]. Minerva Gastroenterologica e Dietologica 1992;38:145-51.
21. Giulidori P, Cortellaro M, Moreo G, Stramentinoli G. Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. European Journal of Clinical Pharmacology 1984;27(1):119-21. [MEDLINE: 85027421]
22. Gorbakov VV, Galik VP, Kirillov SM. Heptral treatment of diffuse hepatic diseases. Terapevticheskii arkhiv 1998;70(10):82-6.
23. Lieber CS. Alcohol and the liver: metabolism of alcohol and its role in hepatic and extrahepatic diseases. The Mount Sinai Journal of Medicine 2000;67(1):84-94. [MEDLINE: 20144273]
24. Lu SC. S-adenosylmethionine. The International Journal of Biochemistry and Cell Biology 2000;32:391-5.
25. Marchesini G, Bugianesi E, Bianchi G, Fabbri A, Marchi E, Zoli M, et al. Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. Clinical Nutrition 1992;11:303-8.
26. Mazzanti R, Arcangeli A, Salvadori G, Smorlesi C, Di Perri T, Auteri A, et al. On the anti-steatosic effects of S-adenosyl-L-methionine in various chronic liver diseases (multicentre study). Current Therapeutic Research, Clinical and Experimental 1979;25(1):25-34.
27. Micali M, Chiti D, Balestra V. Double-blind controlled clinical trial of SAMe administered orally in chronic liver diseases. Current Therapeutic Research 1983;33(6):1004-13.
28. Pons Villegas J. Effect of SAM in alcoholic patients [Efecto de la SAMe en pacientes alcoholicos]. Actas Luso Espanolas de Neurologia Psiquiatria Y Ciencias Afines 1983;11(5):385-9.
29. Rafique S, Guardascione M, Osman E, Burroughs AK. Reversal of hepatic membrane cholesterol deposition in patients with chronic liver disease by S-adenosyl-L-methionine. Clinical Science 1992;83:353-6.
30. Salerno MT, Vendemiale G, Amendola A, Trione T, Palasciano G, Altomare E, et al. Effect of orally administered S-adenosyl-L-methionine (SAMe) in patients with alcoholic liver disease. Digestive Diseases and Sciences 1986;Suppl 31(10):192S.
31. Silvi G, Rina D, Giannelli G. Efficacy of S-adenosyl-L-methionine for the treatment of chronic hepatic diseases [Efficacia della solfoadenosilmetionina (SAMe) nel trattamento delle epatopatie croniche]. La Clinica Terapeutica 1980;92:241-50.
32. Turchetti V, Bellini MA, Leoncini F, Petri F, Trabalzini L, Guerrini M, et al. Blood viscosity and red cell morphology in subjects suffering from cirrhosis before and after treatment with S-adensoyl-L-methionine. Clinical Hemorheology Microcirculation 2000;22(3):215-21.
33. Turpini R, Albergati M, Gili C. Macrocytosis in chronic alcoholism: a tentative correction with vitamin B12, 5-methyltetrahydrofolate, and S-adenosylmethionine. Current Therapeutic Research 1987;41(1):1987.
34. Ahmad I, Rao DN. Chemistry and biology of DNA methyltransferases. Critical Reviews in Biochemistry and Molecular Biology 1996;31(5-6):361-80.
35. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119(6):1637-48.
36. Aleynik SI, Lieber CS. Polyenylphosphatidylcholine corrects the alcohol-induced hepatic oxidative stress by restoring s-adenosylmethionine. Alcohol and Alcoholism 2003;38(3):208-12.
37. Almasio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 1990;40(Suppl 3):111-23.
38. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica Suppl 1994;154:15-8. [: PMID 7941961]
39. Boelsterli UA, Rakhit G, Balazs T. Modulation by S-adenosyl-L-methionine of hepatic Na+, K+- ATPase, membrane fluidity, and bile flow in rats with ethinyl estradiol-induced cholestasis. Hepatology 1983;3(1):12-7.
40. Bombardieri G, Pappalardo G, Bernardi L, Barra D, Di Palma A, Castrini G. Intestinal absorption of S-adenosyl-L-methionine in humans. International Journal of Clinical Pharmacology Therapy and Toxicology 1983;21(4):186-8.
41. Bessa GM. S-adenosyl-L-methionine (SAMe) as antidepressant: mata-analysis of clinical studies. Acta Neurologica Scandinavica 1994;154(Suppl):7-14.
42. Cantoni GL. The nature of the active methyl donor formed enzymatically from L-methionine and adenosinetriphosphate. Journal of the American Chemical Society 1952;74:2942-3.
43. Cantoni GL. S-adenosylmethionine a new intermediate formed enzymatically from L-methionine and adenosine-triphosphate. The Journal of Biological Chemistry 1953;204:403-16.
44. Carretero MV, Latasa MU, Garcia-Trevijano ER, Corrales FJ, Wagner C, Mato JM, et al. Inhibition of liver methionine adenosyltransferase gene expression by 3-methylcolanthrene: protective effect of S-adenosylmethionine. Biochemical Pharmacology 2001;61(9):1119-28.
45. Chawla RK, Bonkovsky HL, Galambos JT. Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale of its use in liver disease. Drugs 1990;40 Suppl 3:98-110.
46. Christensen E, Gluud C. Glucocorticosteroids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995;37(1):113-8. [: PMID: 7672658]
47. Demets DL. Pratical aspects in monitoring: a brief review. Statistics in Medicine 1987;6(7):753-60.
48. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
49. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
50. Finkelstein JD, Cello JP, Kyle WE. Ethanol-induced changes in methionine metabolism in rat liver. Biochemical and Biophysical Research Communications 1974;61(2):525-31.
51. Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Adaptation to methionine excess. The Journal of Biological Chemistry 1986;261(4):1582-7.
52. Flora K, Hahn M, Rosen H, Benner K. Milk Thistle (Silybum marianum) for the therapy of liver disease. The American Journal of Gastroenterology 1998;93(2):139-43.
53. Frezza M. A meta-analysis of therapeutic trials with ademetionine in the treatment of intrahepatic cholestasis [Metanalisi dei trial terapeutici con adenometionina nel trattamento della colestasi intraepatica]. Annali Italiani di Medicina Interna 1993;8(Suppl):48S-51S.
54. Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38(3):389-416.
55. Gluud C. Testosterone and alcoholic cirrhosis. Epidemiologic, pathophysiologic and therapeutic studies in men. Danish Medical Bulletin 1988;35(6):564-75. [: PMID: 3064977]
56. Gluud C, Afroudakis A, Caballeria J, Laskus T, Morgan MY, Rueff B, et al. Diagnosis and treatment of alcoholic liver disease in Europe. Gastroenterology International 1993;6(4):221-30.
57. Gluud C, Nikolova D. Quality assessment of reports on clinical trials in the Journal of Hepatology. Journal of Hepatology 1998;29:321-7.
58. Gluud C. Evidence based medicine in Liver. Liver 1999;19:1-2.
59. Gluud C. Alcoholic hepatitis: no glucocorticosteroids?. Steatohepatitis (NASH and ASH). FALK Symposium 121. Leuschner U, James O, Dancygier H. Dordrecht: Kluwer Academic Publishers, 2001:322-42.
60. Gluud LL. Bias in Clinical Intervention Research. Methodological studies of systematic errors in randomised trials and observational studies (Doctoral dissertation). København: Eget forlag;2005:3-32. Forsvaret den 19. august 2005 ved Københavns Universitet, Det Sundhedsvidenskabelige Fakultet.
61. Hardy ML, Coulter I, Morton SC, Favreau J, Venuturupalli S, Chiappelli F, et al. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evidence Report/Technology Assessment 2003;64:1-3. [: PMID: 12899148]
62. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
63. International Conference on Harmonisation. Code of Federal Regulations & ICH Guidelines. Philadelphia, US: Barnett International/PAREXEL, 1997.
64. Ioannidis JPA, Lau J. What certainty can there be on how much treatment work? Empirical insight from recursive cumulative meta-analyses. 8th International Cochrane Colloquium 2000; Vol. October:21.
65. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
66. Kaye GL, Blake JC, Burroughs AK. Metabolism of exogenous S-adenosyl-L-methonine in patients with liver disease. Drugs 1990;40(Suppl 3):124-8.
67. Kjaergard LL, Nikolova D, Gluud C. Randomised clinical trials in Hepatology: predictors of quality. Hepatology 1999;30:1134-8.
68. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomised trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
69. Kjaergard LL, Gluud C. Funding, disease area, and internal validity of hepatobiliary randomized clinical trials. The American Journal of Gastroenterology 2002;97:2708-13.
70. Kjaergard LL, Frederiksen SL, Gluud C. Validity of randomized clinical trials in gastroenterology from 1964-2000. Gastroenterology 2002;122:1157-60.
71. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S, For the Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clinical and Experimental Research 2003;27:1765-72.
72. Lieber CS, De Carli LM. An experimental model of alcohol feeding and liver injury in the baboon. Journal of Medical Primatology 1974;3(3):153-63.
73. Lieber CS, Casini A, De Carli LM, Kim CI, Lowe N, Sasaki R, et al. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology 1990;11(2):165-72.
74. Lieber CS. Role of S-adenosyl-L-methionine in the treatment of liver diseases. Journal of Hepatology 1999;30:1155-9.
75. Loguercio C, Nardi G, Argenzio F, Aurilio C, Petrone E, Grella A, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol and Alcoholism 1994;29(5):597-604.
76. Manzillo G, Piccinino F, Surrenti C, Frezza M, Giudici GA, Le Grazie C. Multicentre double-blind placebo-controlled study of intravenous and oral S-adenosyl-l-methionine (SAMe) in cholestatic patients with liver disease. Drug Investigation 1992;4(Suppl 4):90-100.
77. Marbet UA, Bianchi L, Meury U, Stalder GA. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease. Journal of Hepatology 1987;4(3):364-72.
78. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacology and Therapeutics 1997;73(3):265-80.
79. Mato JM, Cámara J, Fernández de Paz J, Caballeria L, Coll S, Caballero A, et al. S-adenosylmethionine in alcohol liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Journal of Hepatology 1999;30:1081-9.
80. Mendenhall CL, Anderson S, Garcia-Pont P, Goldenberg S, Kiernan T, Seeff LB, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. New England Journal of Medicine 1984;311(23):1464-70.
81. Mezey E, Caballeria J, Mitchell MC, Pares A, Herlong HF, Rodes J. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomized controlled trial. Hepatology 1991;14(6):1090-6. [: PMID: 1959859]
82. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. The Lancet 1998;352:609-13.
83. Morgan MY. Alcoholic liver disease: natural history, diagnosis, clinical features, evaluation, managment, prognosis and prevention. In: Bircher J, Benhamou J-P, McIntyre N, Rizzetto M, Rodés J editor(s). Oxford Textbook of Clinical Hepatology. Second Edition. Vol. 2, Oxford: Oxford University Press, 1999:1185-238.
84. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992;116(1):78-84. [: PMID 92074715]
85. Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. American Journal of Medicine 1968;44(3):406-20.
86. Poynard T, Barthelemy P, Fratte S, Boudjema K, Doffoel M, Vanlemmens C. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls. The Lancet 1994;344(8291):502-7. [: PMID: 7914613]
87. Poynard T, Naveau S, Doffoel M, Boudjema K, Vanlemmens C, Mantion G, et al. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group. Journal of Hepatology 1999;30(6):1130-7.
88. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. The Cochrane Library (Protocol for a Cochrane Review) 2000, Issue 3.
89. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. The Cochrane Database of Systematic Reviews 2001 Issue 4. Art. No.: CD002800. DOI: 10.1002/14651858.CD002800.
90. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. The Cochrane Database of Systematic Reviews 2001, Issue 4 Art. No.: CD002235. DOI: 10.1002/14651858.CD002235.
91. Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease (Cochrane Review). The Cochrane Database of Systematic Reviews 2003 Issue 1. Art. No.: CD003045. DOI: 10.1002/14651858.CD003045.
92. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. The Cochrane Database of Systematic Reviews 2005 Issue 2. Art. No.: CD002148.pub2. DOI: 10.1002/14651858.CD002148.pub2.
93. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. The Cochrane Database of Systematic Reviews 2005 Issue 2. Art. No.: CD003620.pub2. DOI: 10.1002/14651858.CD003620.pub2.
94. Rubin E, Lieber CS. Alcohol-induced hepatic injury in non alcoholic volunteers. New England Journal of Medicine 1968;278(16):869-76.
95. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
96. Stramentinoli G, Gualano M, Galli-Kienle M. Intestinal absorption of S-adenosyl-L-methionine. The Journal of Pharmacology and Experimental Therapeutics 1979;209(3):323-6.
97. Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamisc. American Journal of Medicine 1987;83(5A):35-42.
98. Sørensen TIA, Orhol M, Bentsen KD, Høybye G, Eghøje K, Christoffersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of developement of cirrhosis. The Lancet 1984;2(8397):241-4.
99. Trinchet JC, Balkau B, Poupon RE, Heintzmann F, Callard P, Gotheil C, et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 1992;15(1):76-81. [: PMID: 1727803]
100. Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scandinavian Journal of Gastroenterology 1989;24:407-15.
101. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Controlled Clinical Trials 1998;19:159-66.
102. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Journal of American Medical Association 1991;266(1):93-8. [: PMID 2046134]